Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 11, 2019. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| April 9, 2019 | Ordinary Shares (25p each) | £15.9193 | 160 shares (aggregate) | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents routine equity compensation acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs (160 shares total across 11 individuals).
- Confirm the transaction price of £15.9193 per share against the market price on April 9, 2019.
- Note that all transactions were acquisitions, not sales, indicating no insider divestment on this date.
- Identify the specific roles of the transacting individuals, including the CEO (Ms E Walmsley) and Company Secretary (Mrs V A Whyte).